Supplementary Table 1: Baseline patient demographics and clinical trial characteristics

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | All trials | Trials commencement period† | | | | *P‡* |
|  |  | 1994-2000 | 2001-2005 | 2006-2010 | 2011-2014 |  |
|  | N=63 | N=10 | N=16 | N=19 | N=18 |  |
| Phase 2 RCTs | 30 (48%) | 5 (50%) | 7 (44%) | 8 (42%) | 10 (56%) | .85 |
| Trials conducted only in Japan | 10 (16%) | 0 (0%) | 3 (19%) | 5 (26%) | 2 (11%) | .16 |
| Response evaluation according to RECIST∫ | 54 (86%) | 5 (50%) | 12 (75%) | 19 (100%) | 18 (100%) | .19 |
| Median trial patients treated with docetaxel | 79 | 78 | 76 | 75 | 105 | .32 |
| Range | 24–710 | 34–129 | 25–710 | 24–697 | 41–425 |  |
| Mean of median age (years) | 61 | 61 | 61 | 60 | 62 | .17 |
| Range | 49–68 | 59–63 | 57–68 | 49–67 | 58–67 |  |
| Mean % males | 68 | 74 | 71 | 66 | 62 | .03 |
| Range | 39–93 | 61–93 | 56–89 | 42–92 | 39–77 |  |
| Mean % performance status 0 or 1 | 92 | 82 | 87 | 95 | 98 | <.0001 |
| Range | 39–100 | 73–88 | 39–100 | 80–100 | 82–100 |  |
| Mean % squamous histology | 26 | 30 | 26 | 27 | 22 | .76 |
| Range | 0–94 | 19–41 | 14–44 | 0–60 | 0–94 |  |
| Mean % second-line patients | 93 | 94 | 97 | 94 | 87 | .20 |
| Range | 17–100 | 7–100 | 82–100 | 63–100 | 17–100 |  |

†The commencement years for two trials was unknown, and they were imputed by year of study publication

‡*P*-value indicates whether there is a trend in the distribution of each factor over the period of trial commencement

∫Two trials used Southwest Oncology Group criteria and seven trials used World Health Organisation criteria

RCTs, Randomized controlled trials; RECIST, Response Evaluation Criteria In Solid Tumors.